| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CRITREVONC.2016.06.002 |
| P698 | PubMed publication ID | 27354233 |
| P50 | author | Giuseppe Curigliano | Q47736732 |
| Darran P O'Connor | Q60618173 | ||
| P2093 | author name string | Ira Jacobs | |
| Julie A Rosenberg | |||
| P2860 | cites work | Development of biosimilars in an era of oncologic drug shortages | Q28082623 |
| Acceptable changes in quality attributes of glycosylated biopharmaceuticals | Q28235143 | ||
| Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey | Q33673144 | ||
| Biosimilar agents in oncology/haematology: from approval to practice | Q34892411 | ||
| Presently available biosimilars in hematology-oncology: G-CSF. | Q37977011 | ||
| Biosimilars: what clinicians should know | Q38055115 | ||
| Clinical experience with Zarzio® in Europe: what have we learned? | Q38125609 | ||
| Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation | Q38186025 | ||
| Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. | Q39059388 | ||
| Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. | Q42783305 | ||
| Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization | Q62476141 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 131-137 | |
| P577 | publication date | 2016-06-15 | |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | Biosimilars: Extrapolation for oncology | |
| P478 | volume | 104 |
| Q57173064 | Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America |
| Q50107702 | Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained. |
| Q54959955 | Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience? |
| Q92805646 | Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim |
| Q64056304 | Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology |
| Q55111318 | Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). |
| Q92984377 | Physicochemical Stability of Monoclonal Antibodies: A Review |
| Q93139736 | The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars |
| Q50115805 | The process defines the product: what really matters in biosimilar design and production? |
| Q89716976 | Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars |
Search more.